Literature DB >> 6307685

Efficacy of ceftriaxone and gentamicin in an abscess model.

E Rubinstein, M Pritsch, Z Mark, J Spicehandler.   

Abstract

The therapeutic efficacy of ceftriaxone and gentamicin was investigated in a foreign body induced abscess model in the rat by implanting a dialysis tube contaminated with Klebsiella pneumoniae into the subcutaneous tissue. Animals were treated for four days with ceftriaxone, gentamicin, and their combination starting immediately following or 48 h after the implantation. Peak free ceftriaxone and gentamicin abscess fluid levels were 4.3 and 2.6 mcg/ml, which were 7.3% and 37.5% of peak blood levels respectively. Both agents persisted longer in abscess fluid than in blood. Ceftriaxone inhibited the development of abscess formation when administered shortly after the implantation of the contaminated foreign body whereas gentamicin alone was without beneficial effect. When administered after 48 h ceftriaxone was less effective than immediately after implantation and gentamicin was again without any therapeutic effect. The effect of the combination of ceftriaxone and gentamicin was slightly better than ceftriaxone alone. Low oxygen tension may be an explanation for the lack of bactericidal effect of gentamicin. Ceftriaxone may be more suitable for the therapy of closed space infections caused by susceptible microorganisms than gentamicin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6307685     DOI: 10.1007/bf02019970

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  12 in total

1.  DELIVERY OF ANTIMICROBIAL DRUGS ACROSS INFLAMMATORY MEMBRANE IN RABBITS.

Authors:  R McCune
Journal:  J Clin Invest       Date:  1960-06       Impact factor: 14.808

2.  PO2, pH, and redox potential of experimental abscesses.

Authors:  R C Hays; G L Mandell
Journal:  Proc Soc Exp Biol Med       Date:  1974-10

3.  Pathophysiology of tissue fluid.

Authors:  J S Calnan; J J Pflug; G D Chisholm; L M Taylor
Journal:  Proc R Soc Med       Date:  1972-08

4.  Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.

Authors:  R Reiner; U Weiss; U Brombacher; P Lanz; M Montavon; A Furlenmeier; P Angehrn; P J Probst
Journal:  J Antibiot (Tokyo)       Date:  1980-07       Impact factor: 2.649

5.  Gentamicin antibacterial activity in the presence of human polymorphonuclear leukocytes.

Authors:  P Vaudaux; F A Waldvogel
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

6.  Efficacy of parenteral antibiotics in the treatment of experimentally induced intraabdominal sepsis.

Authors:  R L Nichols; J W Smith; E N Fossedal; R E Condon
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

7.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

8.  Interaction of intraleukocytic bacteria and antibiotics.

Authors:  G L Mandell
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

9.  Comparative in vitro activity of three aminoglycosidic antibiotics: BB-K8, kanamycin, and gentamicin.

Authors:  P K Yu; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

Review 10.  Therapeutic efficacy of 29 antimicrobial regimens in experimental intraabdominal sepsis.

Authors:  J G Bartlett; T J Louie; S L Gorbach; A B Onderdonk
Journal:  Rev Infect Dis       Date:  1981 May-Jun
View more
  2 in total

Review 1.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 2.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.